Samsung E&A Corrects End Date of 1.77 Trillion Won P5 Project Contract with Samsung Biologics
Samsung E&A disclosed a correction to its single sale/supply contract for the P5 Project with Samsung Biologics, amounting to KRW 1.7707 trillion (16.67% of revenue)
The contract end date was corrected to April 30, 2026, with actual signing delayed to May 22, 2026 due to negotiation delays
No changes to contract amount or terms; project involves construction of a biopharmaceutical production facility (180,000 liters)
KOSPI Filing Information
Filing: [Correction of Description] Conclusion of Single Sale and Supply Contract